Study to Evaluate the Real-World Effectiveness, Safety and Tolerability of Treatment With Apremilast in Psoriatic Arthritis Patients Followed in Canadian Routine Care (APPRAISE)

CompletedOBSERVATIONAL
Enrollment

102

Participants

Timeline

Start Date

July 31, 2018

Primary Completion Date

April 12, 2021

Study Completion Date

March 30, 2022

Conditions
Arthritis, Psoriatic
Interventions
DRUG

Apremilast

Apremilast

Trial Locations (19)

L4M 6L2

The Waterside Clinic, Barrie

L7L 0B7

The Arthritis and Osteoporosis Centre, Burlington

L8N 1Y2

Adachi Medicine Professional Corporation, Hamilton

L5M 2V8

Credit Valley Rheumatology, Mississauga

H2L 1S6

Institut de Recherche en Rhumatologie de Montréal, Montreal

H4A 3T2

Applied Medical Informatics Research Inc. (A.M.I.R.), Montreal

V6Z 2C7

Brent Appleton Clinic New Westminster, New Westminster

L6M 4J2

Dr. A. M. Jaroszynska Rheumatology and Osteoporosis Clinic, Oakville

V2A 4Z1

Drs M&W Teo, Penticton

G1V 3M7

Groupe de recherche en maladies osseuses Inc., Québec

G5L 8W1

Centre de Rhumatologie de l'Est du Quebec, Rimouski

S7N 4A4

Polmed Research Inc., Saskatoon

J1J 2E3

Clinique Jacques Cartier, Sherbrooke

A1A 5B8

St. Clare's Mercy Hospital, St. John's

B1S 3N1

Dr. Juris Lazovskis Incorporated, Sydney

M5T 2S8

Toronto Western Hospital, University Health Network, Toronto

M9C 5N2

Arthur Karasik Medicine Professional Inc., Toronto

V5Z 1J9

Dr. Jonathan D. Chan Inc., Vancouver

N8X 5A6

Dr. Sabeen Anwar Medicine Professional Corporation, Windsor

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Amgen

INDUSTRY

NCT03608657 - Study to Evaluate the Real-World Effectiveness, Safety and Tolerability of Treatment With Apremilast in Psoriatic Arthritis Patients Followed in Canadian Routine Care (APPRAISE) | Biotech Hunter | Biotech Hunter